The Most Important Marijuana Growth Chart You'll Ever See
A new report sheds light on where cannabis growth will come from in the years that lie ahead.
Is CBD Bad for Your Liver? The Shocking Findings of 1 New Study
Is the public's faith in cannabidiol misplaced?
BDS Analytics, Arcview Project $40B In Global Cannabis Spending By 2024
Arcview Market Research and BDS Analytics have published the seventh edition of their "State of Legal Cannabis Markets" report. The growth of the global cannabis market comes on the back of liberalization...
Opinion: Medical Marijuana Is a Terrible Investment
Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.
Is GW Pharmaceuticals plc (GWPH) A Good Stock To Buy?
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment...
They Meet, We Rally
They Meet, We Rally
5 Top European Stocks to Buy on ECB's Hints of More Stimulus
The ECB hints at more policy stimulus, making the conditions favorable for these stocks.
4 Hot Cannabis Stocks Growing Now
It’s not often you get to witness the opening of a whole new market sector. After last year’s move by the Canadian Parliament to fully legalize marijuana and cannabis products throughout the country, and...
GW Pharmaceuticals (GWPH) Should Find a Place in Your Portfolio
June has been one roller coaster ride for cannabis stocks. First, the FDA reported that CBD be treated like a drug causing cannabis stocks to decline, then a slurry of upgrades caused some cannabis stocks...
BIIB Is For Buy-O-Gen
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological,...
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has developed an oral formulation of purified cannabidiol (CBD), approved as Epidiolex® in the U.S. by the U.S. Food and Drug Administration (FDA) for seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, two rare and severe early-onset, drug-resistant epilepsy syndromes. This is the first cannabis plant-derived medicine ever approved by the FDA and it has been rescheduled by the U.S. DEA to a schedule V. The medicine was launched in the US as a prescription medicine by our US operating subsidiary, Greenwich Biosciences Inc., on November 1, 2018. GW has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with an expected decision date in early 2019.
GW successfully developed the world’s first prescription medicine derived from the cannabis plant, called Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US), which is now approved in over 25 countries outside of the US for the treatment of spasticity due to multiple sclerosis. GW continues to research and develop Sativex.
The company has a deep pipeline of additional clinical stage cannabinoid product candidates under development for both orphan and non-orphan indications with a particular focus on neurological conditions.
GW Pharmaceuticals was founded in 1998 and is listed on the NASDAQ Global Market (GWPH). The company has operations in both the US and the UK.